Fertility and gonadal function after adjuvant therapy in women diagnosed with a malignant ovarian germ cell tumor (MOGCT) during the "cisplatin era".
暂无分享,去创建一个
H. Salvesen | J. Kærn | T. Paulsen | E. Rokkones | A. Vereide | O. Solheim | Claes G. Tropé | S. Fosså | Bjørn Hagen
[1] S. Fosså,et al. Malignant ovarian germ cell tumors: presentation, survival and second cancer in a population based Norwegian cohort (1953-2009). , 2013, Gynecologic oncology.
[2] D. Matei,et al. Updates in the management of ovarian germ cell tumors. , 2013, American Society of Clinical Oncology educational book. American Society of Clinical Oncology. Annual Meeting.
[3] Y. Englert,et al. Gonadotropin-releasing hormone agonist for the prevention of chemotherapy-induced ovarian failure in patients with lymphoma: 1-year follow-up of a prospective randomized trial. , 2013, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[4] M. Geraci,et al. Comparative incidence patterns and trends of gonadal and extragonadal germ cell tumors in England, 1979 to 2003 , 2012, Cancer.
[5] J. Ng,et al. Malignant ovarian germ-cell tumours. , 2012, Best practice & research. Clinical obstetrics & gynaecology.
[6] H. Earl,et al. Multidisciplinary management of malignant ovarian germ cell tumours. , 2011, Gynecologic oncology.
[7] K. Main,et al. Serum levels of anti-Müllerian hormone as a marker of ovarian function in 926 healthy females from birth to adulthood and in 172 Turner syndrome patients. , 2010, The Journal of clinical endocrinology and metabolism.
[8] J. Visser,et al. Assessment of ovarian reserve in adult childhood cancer survivors using anti-Müllerian hormone. , 2008, Human reproduction.
[9] M. Fallat,et al. Preservation of Fertility in Pediatric and Adolescent Patients With Cancer , 2008, Pediatrics.
[10] T. Tanbo. [Is fertility of the population changed?]. , 2008, Tidsskrift for den Norske laegeforening : tidsskrift for praktisk medicin, ny raekke.
[11] R. Pieters,et al. Anti-Mullerian hormone is a sensitive serum marker for gonadal function in women treated for Hodgkin's lymphoma during childhood. , 2007, The Journal of clinical endocrinology and metabolism.
[12] D. Gershenson. Management of ovarian germ cell tumors. , 2007, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[13] Anna M. Miller,et al. Reproductive and sexual function after platinum-based chemotherapy in long-term ovarian germ cell tumor survivors: a Gynecologic Oncology Group Study. , 2007, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[14] G. Rustin,et al. Malignant ovarian germ cell tumors: identification of novel prognostic markers and long-term outcome after multimodality treatment. , 2006, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[15] P. Patrizio,et al. American Society of Clinical Oncology recommendations on fertility preservation in cancer patients. , 2006, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[16] C. Muller,et al. Incidence and Survival Rates for Female Malignant Germ Cell Tumors , 2006, Obstetrics and gynecology.
[17] J. Habbema,et al. Serum antimullerian hormone levels best reflect the reproductive decline with age in normal women with proven fertility: a longitudinal study. , 2005, Fertility and sterility.
[18] M. Seckl,et al. Infertility rates following POMB/ACE chemotherapy for male and female germ cell tumours – a retrospective long-term follow-up study , 2003, British Journal of Cancer.
[19] C. Mangioni,et al. Survival and reproductive function after treatment of malignant germ cell ovarian tumors. , 2001, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[20] N. Hacker,et al. Conservative surgery to preserve ovarian function in patients with malignant ovarian germ cell tumors , 2000, Cancer.
[21] J. Pont,et al. Fertility after chemotherapy for testicular germ cell cancer. , 1997, Fertility and sterility.
[22] C. Bokemeyer,et al. Evaluation of long-term toxicity after chemotherapy for testicular cancer. , 1996, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[23] D. Gershenson. Menstrual and reproductive function after treatment with combination chemotherapy for malignant ovarian germ cell tumors. , 1988, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[24] R. Schilsky,et al. Gonadal dysfunction in patients receiving chemotherapy for cancer. , 1980, Annals of internal medicine.